Thiogenesis Therapeutics, Corp.: Thiogenesis Engages Brisco Capital for Investor Relations
Thiogenesis Therapeutics (TSXV: TTI, OTCQB: TTIPF) hired Brisco Capital for investor relations, paying $6,000 monthly plus stock options. The company plans to amend its equity incentive plan, increasing reserved shares from 9,099,095 to 13,995,931, subject to shareholder approval. Thiogenesis develops sulfur-based therapeutics for rare diseases, with lead candidate TTI-0102 in clinical development.
How this was made
The 30-second read
Why it matters
The agreement provides monthly cash and stock options, while the plan amendment increases the pool of shares available for future grants, both aimed at supporting future financing and talent retention.
Market read
The news is a low‑impact corporate‑action announcement for a micro‑cap biotech, unlikely to move the broader market.
What to watch
Potential future dilution from the stock option grant could affect existing shareholders.
Background
Thiogenesis Therapeutics, a clinical-stage biotech on the TSX Venture Exchange, announced a new investor‑relations agreement and an amendment to its equity incentive plan.
Market effects
minor impact on biotech IR services sector
limited to Canadian microcap investors
low
Counterpoint
The IR engagement may not materially affect share price given the company's size and liquidity.
Key entities
- companyThiogenesis Therapeutics Corp.
Clinical‑stage biotech developing sulfur‑based therapeutics.
- service providerBrisco Capital Partners Corp.
Investor‑relations firm hired to assist Thiogenesis.
